Selected recent publications:

• Zeng X, Hood BL, Zhao T, Conrads TP, Sun M, Gopalakrishnan V, Grover H, Day RS, Weissfeld JL, Wilson DO, Siegfried JM, Bigbee WL. Lung cancer serum biomarker discovery using label-free liquid chromatography-tandem mass spectrometry. Journal of Thoracic Oncology [Internet]. 2011;6(4):725-34.
• Zeng X, Hood BL, Sun M, Conrads TP, Day RS, Weissfeld JL, Siegfried JM, Bigbee WL. Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. Journal of Proteome Research [Internet]. 2010;9(12):6440-9.
• Day RS. Failsafe automation of phase II clinical trial interim monitoring for stopping rules. Clinical Trials [Internet]. 2010;7(1):78-84.
• Wang M, Day R. Adaptive bayesian design for phase i dose-finding trials using a joint model of response and toxicity. J Biopharm Stat [Internet]. 2010;20(1):125-44.
• Boak MB, M'ikanatha NM, Day RS, Harrison LH. Internet death notices as a novel source of mortality surveillance data. Am J Epidemiol [Internet]. 2008;167(5):532-9.
• Day RS, Davis M. Clinical trial interim monitoring support: Requirements and implementation. AMIA ...Annual Symposium proceedings / AMIA Symposium.AMIA Symposium [Internet]. 2007:926.
• Piwowar HA, Day RS, Fridsma DB. Sharing detailed research data is associated with increased citation rate. PLoS ONE [Internet]. 2007;2(3)
• Day RS. Challenges of biological realism and validation in simulation-based medical education. Artif Intell Med [Internet]. 2006;38(1):47-66.
• Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel M, Finn OJ. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunology, Immunotherapy [Internet]. 2005;54(3):254-64.
• Day RS, Manning BK, Garrott D, Brufsky AM, Baar J, Egorin MJ, Shirey WE, Friedman C. Evaluation of the OncoTCap (oncology thinking cap) simulation in teaching medical students about clinical trials: Some successes and some surprises. Journal of Cancer Education [Internet]. 2004;19(3):149-55.
• Welsh C, Day R, McGurk C, Masters JRW, Wood RD, Köberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. International Journal of Cancer [Internet]. 2004;110(3):352-61.
• Shackney SE, Smith CA, Pollice A, Brown K, Day R, Julian T, Silverman JF. Intracellular patterns of her-2/neu, ras, and ploidy abnormalities in primary human breast cancers predict postoperative clinical disease-free survival. Clinical Cancer Research [Internet]. 2004;10(9):3042-52.
• Matin K, Egorin MJ, Ballesteros MF, Smith DC, Lembersky B, Day RS, Johnson CS, Trump DL. Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate. Cancer Chemother Pharmacol [Internet]. 2002;50(3):179-85.
• Rose C, Green M, Webber S, Kingsley L, Day R, Watkins S, Reyes J, Rowe D. Detection of epstein-barr virus genomes in peripheral blood B cells from solid-organ transplant recipients by fluorescence in situ hybridization. J Clin Microbiol [Internet]. 2002;40(7):2533-44.
• Hmelo-Silver CE, Nagarajan A, Day RS. "It's harder than we thought it would be": A comparative case study of expert-novice experimentation strategies. Science Education [Internet]. 2002;86(2):219-43.

CONTACT INFORMATION:

Dr. Roger Day
Phone: (412) 383-1573
Email:day@upci.pitt.edu